Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 2Genitourinary 2Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 24Neoplasm Metastasis 11Stomach Neoplasms 6Pancreatic Neoplasms 4Ovarian Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Salivary Gland Neoplasms 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Neoplasms 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1

Interventions

Gemcitabine 58130-nm albumin-bound paclitaxel 35Specimen Handling 26Fluorouracil 22Albumin-Bound Paclitaxel 22Magnetic Resonance Spectroscopy 21Leucovorin 21Irinotecan 21Oxaliplatin 19Biopsy 17Taxes 16pembrolizumab 15Cyclophosphamide 12Cisplatin 11fludarabine 10Cetuximab 9Capecitabine 8durvalumab 7Radiosurgery 7Nivolumab 7Carboplatin 7irinotecan sucrosofate 6dehydroftorafur 6Pemetrexed 6olaparib 5Radiotherapy 5Ipilimumab 5Erlotinib Hydrochloride 5Blood Specimen Collection 5trastuzumab deruxtecan 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × trastuzumab deruxtecan × 90 days × Clear all
NCT05417594 2026-06-02

CERTIS1

AstraZeneca

Phase 1/2 Recruiting
695 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologic

Astrocytoma, Breast Neoplasms, Fallopian Tube Neoplasms, Glioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07619521 2026-06-02

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
31 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT07124000 2026-06-01

DP-04

AstraZeneca

Recruiting
100 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT04482309 2026-04-09

DPT02

AstraZeneca

Phase 2 Active not recruiting
477 enrolled 1 FDA
Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡